The devil in the details

26 Sep 2006 By Robert Cyran

Midcap drug makers face an ugly future. So Serono, Altana and Schwarz Pharma have all pulled the ripcord in the past month. Competitors Bayer, Novo Nordisk and Akzo Noble would seem like natural followers. But the devil is in the details.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)